{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Morse LR"],"funding":["Craig H. Neilsen Foundation"],"pagination":["e1301"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12173286"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(4)"],"pubmed_abstract":["<h4>Objective</h4>Assess feasibility, safety, and tolerability of 3 months of oral brivaracetam for severe (9-10/10) spinal cord injury-related neuropathic pain.<h4>Methods</h4>We conducted a multisite pilot study where adults were randomized to 3 months of brivaracetam (100 mg BID) or placebo. Pain was assessed via the Brief Pain Inventory, the International Spinal Cord Injury Pain Basic Dataset (version 2.0), and a daily pain diary.<h4>Results</h4>We enrolled 24 participants across 2 sites and 14 participants were included in the final analysis (n = 8 placebo, n = 6 brivaracetam). The drug was tolerated with expected, nonserious side effects (nausea if taken on an empty stomach, fatigue that improved after 2-3 days). Side effects were more common in the brivaracetam group (73%, n = 8 vs "],"journal":["Pain reports"],"pubmed_title":["Brivaracetam for spinal cord injury-related neuropathic pain: results of a pilot double-blinded, randomized, placebo-controlled clinical trial."],"pmcid":["PMC12173286"],"funding_grant_id":["652052"],"pubmed_authors":["Anderton G","Goldstein R","Wudlick R","DeVries B","Nguyen N","Stillman M","Battaglino RA","Falci SP","Welch A","Linnman C","Glossner J","Morse LR","Battaglino AL"],"additional_accession":[]},"is_claimable":false,"name":"Brivaracetam for spinal cord injury-related neuropathic pain: results of a pilot double-blinded, randomized, placebo-controlled clinical trial.","description":"<h4>Objective</h4>Assess feasibility, safety, and tolerability of 3 months of oral brivaracetam for severe (9-10/10) spinal cord injury-related neuropathic pain.<h4>Methods</h4>We conducted a multisite pilot study where adults were randomized to 3 months of brivaracetam (100 mg BID) or placebo. Pain was assessed via the Brief Pain Inventory, the International Spinal Cord Injury Pain Basic Dataset (version 2.0), and a daily pain diary.<h4>Results</h4>We enrolled 24 participants across 2 sites and 14 participants were included in the final analysis (n = 8 placebo, n = 6 brivaracetam). The drug was tolerated with expected, nonserious side effects (nausea if taken on an empty stomach, fatigue that improved after 2-3 days). Side effects were more common in the brivaracetam group (73%, n = 8 vs ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-06-02T22:29:50.219Z","creation":"2026-04-21T03:13:46.043Z"},"accession":"S-EPMC12173286","cross_references":{"pubmed":["40528843"],"doi":["10.1097/PR9.0000000000001301"]}}